Wider legalization has come with a specific, well-documented shift in public perception: cannabis increasingly gets treated as effectively risk-free, especially compared to alcohol. New research published this week in JAMA Psychiatry complicates that picture considerably cannabis use disorder is climbing sharply among U.S. adults, even as alcohol use disorder has been declining over the same period.
The study, analyzing nationally representative survey data from nearly 187,000 U.S. adults between 2021 and 2024, found the number of adults with cannabis use disorder rose from 15.3 million to 19.4 million over just three years. Broken down by prevalence: among men, cannabis use disorder rose from 7.3% to 9.3%; among women, from 4.5% to 5.6%. Moderate-to-severe cases specifically rose too from 3.1% to 4.1% among men, and 1.7% to 2.5% among women with the increases most pronounced among middle-aged and older adults. Over the same period, adult alcohol use disorder actually declined, from 28.8 million to 27.1 million cases nationally a genuinely striking divergence between the two substances.
Researchers point to three converging factors, not a single cause:
- Rising potency. Average THC concentration in cannabis products has increased three- to five-fold over the past two decades today's products are, in a meaningful sense, not the same substance many people remember from decades ago.
- Expanding legalization and access. Broader legal availability has been directly linked to increased use in multiple studies, including research specifically finding legalization associated with increased use among adults with historically lower consumption rates.
- Declining perceived risk. Public perception of cannabis as low-risk has grown even as the products themselves have gotten more potent a gap between perceived and actual risk that researchers specifically flag as a concern.
Cannabis use disorder isn't about frequency of use alone it's a clinical diagnosis involving difficulty controlling cannabis use despite negative consequences: interference with work, school, or relationships, tolerance requiring more to achieve the same effect, withdrawal symptoms when stopping, and continued use despite awareness of harm. Among regular users, an estimated 20-30% may meet criteria for cannabis use disorder, with risk increasing alongside daily use, early age of first use, and higher-potency products specifically.
The research authors were direct about this: the findings challenge the widespread perception that cannabis carries little addictive potential. It's true that cannabis carries different risks than alcohol or opioids the DEA reports no documented cases of fatal overdose attributed to cannabis alone, for instance. But "lower overdose risk than opioids" and "not addictive" are different claims, and the growing prevalence data doesn't support the second one.
There is currently no FDA-approved medication specifically for cannabis use disorder, which puts more weight on behavioral treatment approaches the same evidence-based therapies used across substance use disorders generally:
- Cognitive Behavioral Therapy (CBT) addressing thought patterns and situational triggers associated with use
- Motivational Enhancement Therapy particularly useful given how many people with cannabis use disorder haven't fully recognized it as a problem, given the substance's "harmless" public reputation
- Contingency Management reward-based reinforcement for verified abstinence, discussed in more detail in our contingency management guide
Risk appears meaningfully elevated for people who begin regular use during adolescence one estimate suggests up to 45% of cannabis users aged 12-17 meet criteria for a substance use disorder, considerably higher than adult rates, and regular adolescent use has been associated with measurable effects on cognitive development. Encouragingly, teen cannabis use itself hasn't risen the way many feared following legalization 2024 survey data actually shows a decline in past-year use among 12th graders compared to the prior year but perceived risk among teens has continued falling even as use holds roughly steady, a gap researchers describe as its own distinct concern.
Frequently asked questions
New JAMA Psychiatry research based on nationally representative survey data found a genuine increase in prevalence from 15.3 million to 19.4 million affected U.S. adults between 2021 and 2024 not simply improved detection.
The comparison is more nuanced than a simple ranking. Recent data actually shows cannabis use disorder rising while alcohol use disorder has been declining over the same period, though the two substances carry different risk profiles overall, including cannabis's lower association with fatal overdose.
Researchers point to a combination of rising average THC potency, expanded legal access, and declining public perception of risk as converging factors, rather than any single cause.
No FDA-approved medication currently exists specifically for cannabis use disorder, making evidence-based behavioral therapies CBT, motivational enhancement therapy, and contingency management the primary treatment approaches.
Yes estimates suggest a substantially higher share of adolescent cannabis users meet criteria for a substance use disorder compared to adult users, and regular use during adolescence has been linked to measurable effects on cognitive development.
Estimates suggest roughly 20-30% of regular users may meet diagnostic criteria, with risk rising alongside daily use, earlier age of first use, and higher-potency products.
This article was reviewed by the RehabsNearMe Editorial Team for accuracy, clarity, and relevance. Information may be sourced from publicly available treatment resources, government agencies, and healthcare references where applicable.
Last reviewed: August 2026
Related articles
Resources
